Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
复制标题
DOI：
10.1007/s00280-016-3070-2
复制
发表时间：
2016-07
影响因子：
3
通讯作者：
Utsunomiya A
中科院分区：
文献类型：
--
作者：
Ogura M;Ishida T;Tsukasaki K;Takahashi T;Utsunomiya A
众所周知，自然杀伤 (NK) 细胞是介导抗体依赖性细胞毒性 (ADCC) 的最重要的效应细胞，ADCC 是抗体药物的重要作用机制。我们评估了化疗对接受长春新碱-环磷酰胺-多柔比星-泼尼松 (VCAP)、多柔比星-雷莫司汀-泼尼松 (AMP) 和长春地辛-依托泊苷-卡铂-泼尼松 (VECP) (mLSG15) 或 mLSG15 样 (-L) 方案的患者的细胞数量和 NK 细胞活性的影响，该方案是化疗的标准方案之一。护理新诊断的成人 T 细胞白血病 - 淋巴瘤 (ATL)，或环磷酰胺 - 阿霉素 - 长春新碱 - 泼尼松 (CHOP) 或 CHOP-L 方案，这是 ATL 和外周 T 细胞淋巴瘤 (PTCL) 的另一种护理标准。分别使用流式细胞术和 51Cr 释放测定法评估淋巴细胞和 NK 细胞的数量以及 NK 细胞活性。共有 26 名未经治疗的 ATL 或 PTCL 患者入组，其中 25 名患者的血液样本可进行评估。 mLSG15/-L治疗后ATL中的NK细胞数量减少，且在VECP治疗前（每个周期的第15-17天）NK细胞数量的减少程度比VCAP治疗前（每个周期的第1天）更为显着。 CHOP/-L处理后ATL中的NK细胞数量也减少。有趣的是，NK细胞活性在治疗后表现出增加的趋势。 CHOP/-L方案治疗后PTCL中NK细胞数量并未减少，但治疗后活性略有下降。这些结果表明化疗药物对 NK 细胞的影响根据疾病类型和化疗强度而变化。
Natural killer (NK) cells are well known to be the most important effector cells mediating antibody-dependent cellular cytotoxicity (ADCC) which is an important mechanism of action of antibody drugs. We evaluated the effects of chemotherapy on the cell number and activity of NK cells from patients who received the vincristine–cyclophosphamide–doxorubicin–prednisone (VCAP), doxorubicin–ranimustine–prednisone (AMP), and vindesine–etoposide–carboplatin–prednisone (VECP) (mLSG15) or mLSG15-like (-L) regimen, which is one of the standard of cares for newly diagnosed adult T-cell leukemia–lymphoma (ATL), or the cyclophosphamide–doxorubicin–vincristine–prednisone (CHOP) or CHOP-L regimen which is another standard of care for ATL and peripheral T-cell lymphoma (PTCL). The number of lymphocytes and NK cells, and NK cell activity, were assessed using flow cytometry and a 51Cr release assay, respectively. A total of 26 patients with untreated ATL or PTCL were enrolled, and blood samples from 25 patients were evaluable. NK cell number in ATL decreased after mLSG15/-L treatment, and the degree of decrease in the NK cell number was more prominent just before VECP therapy (Day 15–17 of each cycle) than just before VCAP therapy (Day 1 of each cycle). The NK cell number in ATL after CHOP/-L treatment also decreased. Interestingly, the NK cell activity showed a tendency to increase after the treatment. NK cell number in PTCL did not decrease by CHOP/-L regimen, but the activity was slightly decreased after the treatment. These results indicate that the effects of chemotherapeutic agents on NK cells vary according to the disease type and intensity of chemotherapy.